Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

RUNX3 Facilitates Growth of Ewing Sarcoma Cells
Bledsoe, Krista L., McGee‐Lawrence, Meghan E. , Camilleri, Emily T. , Riester, Scott M. , Wijnen, André J. van , Oliveira, André M. , Camilleri, Emily , Wang, Xiaoke , Westendorf, Jennifer J. , van Wijnen, Andre J , McGee-Lawrence, Meghan E , Camilleri, Emily

Journal of Cellular Physiology | May 8, 2014 | Volume: 229 | Issue: 12 | Pages: 2049-2056

10.1002/jcp.24663 | PMID 24812032 Get It

Ewing sarcoma is an aggressive pediatric small round cell tumor that predominantly occurs in bone. Approximately 85% of Ewing sarcomas harbor the EWS/FLI fusion protein, which arises from a chromosomal translocation, t(11:22)(q24:q12). EWS/FLI interacts with numerous lineage‐essential transcription factors to maintain mesenchymal progenitors in an undifferentiated state. We previously showed that EWS/FLI binds the osteogenic transcription factor RUNX2 and prevents osteoblast differentiation. In this study, we investigated the role of another Runt‐domain protein, RUNX3, in Ewing sarcoma. RUNX3 participates in mesenchymal‐derived bone formation and is a context dependent tumor suppressor and oncogene. RUNX3 was detected in all Ewing sarcoma cells examined, whereas RUNX2 was detected in only 73% of specimens. Like RUNX2, RUNX3 binds to EWS/FLI via its Runt domain. EWS/FLI prevented RUNX3 from activating the transcription of a RUNX‐responsive reporter, p6OSE2. Stable suppression of RUNX3 expression in the Ewing sarcoma cell line A673 delayed colony growth in anchorage independent soft agar assays and reversed expression of EWS/FLI‐responsive genes. These results demonstrate an important role for RUNX3 in Ewing sarcoma. J. Cell. Physiol. 229: 2049–2056, 2014. © 2014 Wiley Periodicals, Inc.
Transition from intravenous or subcutaneous prostacyclin therapy to inhaled treprostinil in patients with pulmonary arterial hypertension: a retrospective case series
Enderby, Cher Y. , Soukup, Mikka, Omari, Mahmoud Al , Zeiger, Tanya, Burger, Charles D.

Journal of Clinical Pharmacy and Therapeutics | May 8, 2014 | Volume: 39 | Issue: 5 | Pages: 496-500

10.1111/jcpt.12170 | PMID 24806480 Get It

A Phase I Dose-Finding Study of the Novel Toll-like Receptor 8 Agonist VTX-2337 in Adult Subjects with Advanced Solid Tumors or Lymphoma
Northfelt, Donald W. , Ramanathan, Ramesh K., Cohen, Peter A. , Hoff, Daniel D. Von , Weiss, Glen J., Dietsch, Gregory N., Manjarrez, Kristi L., Randall, Tressa D., Hershberg, Robert M., Von Hoff, Daniel D

Clinical Cancer Research | May 8, 2014 | Volume: 20 | Issue: 14 | Pages: 3683-3691

10.1158/1078-0432.ccr-14-0392 | PMID 24807889 Get It

Abstract Purpose: This phase I, open-label, uncontrolled, ascending-dose study explored the safety, maximum tolerated dose (MTD), pharmacokinetics, and pharmacology of the TLR8 agonist VTX-2337 in subjects with advanced solid tumors or lymphoma. Experimental Design: VTX-2337 doses (0.1–3.9 mg/m2) were administered subcutaneously on days 1, 8, and 15 of each 28-day cycle. Safety/tolerability assessments included adverse events (AE); physical, ophthalmologic, and laboratory evaluations; and electrocardiograms. Dose-limiting toxicities (DLT) were evaluated during the first cycle. Pharmacokinetics were evaluated after the first dose. Plasma samples were quantitatively assessed for chemokines, cytokines, and other inflammatory mediators. Antitumor activity was assessed. Results: Thirty-three subjects were enrolled in 8 cohorts and received an average of 2 treatment cycles (range, 1–8 cycles). Most AEs were grades 1 to 2; the most common drug-related AEs were injection site reactions, chills, pyrexia, and influenza-like illness. One DLT was reported: grade 3 hypotension (3.9 mg/m2). The MTD was considered the highest dose administered. Peak drug plasma levels and total systemic exposure were generally dose proportional. At doses ≥0.4 mg/m2, increases above baseline levels were observed for plasma levels of G-CSF, monocyte chemoattractant protein-1, macrophage inflammatory protein-1β, and TNFα. Eight subjects (24.2%) had a best response of stable disease (median duration, 54.5 days). Conclusions: VTX-2337 is clinically well tolerated and biologically active with a predictable pharmacokinetic profile. Suitable doses for testing in combination studies were identified. Phase II placebo-controlled studies of VTX-2337 in combination with doxorubicin in ovarian cancer, and in combination with platinum chemotherapy, 5 FU, and cetuximab in head and neck cancer have been initiated (NCT #01666444 and NCT#01836029). Clin Cancer Res; 20(14); 3683–91. ©2014 AACR.
Optimizing resection of sessile serrated polyps
Sweetser, Seth , Baron, Todd H.

Endoscopy | May 7, 2014 | Volume: 46 | Issue: S 01 | Pages: E231-E231

10.1055/s-0034-1365379 | PMID 24806372 Get It

The Fuzzy Edge of CAM Use: Challenges in What Constitutes CAM Use in Self-Administered Questionnaires
Leppin, Aaron L. , Yost, Kathleen J. , Tilburt, Jon C. , James, Katherine L.

The Journal of Alternative and Complementary Medicine | May 7, 2014 | Volume: 20 | Issue: 5 | Pages: A130-A130

10.1089/acm.2014.5348.abstract Get It

What Gets Said About CAM in Cancer Care: Preliminary Descriptive Data from a Qualitative Content Analysis
Kumbamu, Ashok , James, Katherine M. , Leppin, Aaron L. , Geller, Gail , Tilburt, Jon C.

The Journal of Alternative and Complementary Medicine | May 7, 2014 | Volume: 20 | Issue: 5 | Pages: A119-A119

10.1089/acm.2014.5317.abstract Get It

Missed Opportunities: A Descriptive Analysis of CAM Discussions and Practices in the Management of Pain in Oncology Patients
Leppin, Aaron L. , James, Katherine M. , Geller, Gail , Tilburt, Jon C.

The Journal of Alternative and Complementary Medicine | May 7, 2014 | Volume: 20 | Issue: 5 | Pages: A111-A111

10.1089/acm.2014.5295.abstract Get It

Integration of A Stress Management and Resiliency Training (SMART) Program in a Nurse Residency Program: A Feasibility Study
Sood, Amit , Morin, Karen H. , Cutshall, Susan, Douglas, Kristin Vickers, Chesak, Sherry S. , Cutshall, Susanne M. , Ridgeway, Jennifer L.

The Journal of Alternative and Complementary Medicine | May 7, 2014 | Volume: 20 | Issue: 5 | Pages: A101-A101

10.1089/acm.2014.5267.abstract Get It

Mind-Body Medicine and Irritable Bowel Syndrome: A Randomized Control Trial Using Stress Reduction and Resiliency Training
Sharma, Varun , Saito, Yuri A. , Amit, Sood, Amit, Sood

The Journal of Alternative and Complementary Medicine | May 7, 2014 | Volume: 20 | Issue: 5 | Pages: A94-A94

10.1089/acm.2014.5248.abstract Get It

Medical Students Familiarity, Experience and Attitudes Towards Complementary and Alternative Medicine
Wahner‐Roedler, Dietlind L. , Loehrer, Laura L., Cha, Stephen , Bauer, Brent A.

The Journal of Alternative and Complementary Medicine | May 7, 2014 | Volume: 20 | Issue: 5 | Pages: A77-A77

10.1089/acm.2014.5202.abstract Get It